Xavier and Yogender stay in the same hostel of same university, Xavier develops infection due to group B meningococcus. After few days Yogender develops infection due to Group - C meningococcus. All the following are true statement except:
Ans. is 'c' i.e., Vaccine prophylaxis of contacts of Xavier style="font-size: 1.04761904761905em; font-family: Times New Roman, Times, serif">Ref: For Group B Meningococci no vaccine is available as polysacchride capsule of Group B is poorly immunogenic and it is also encephalitogenic due to cross reactive antigen on neural cells.* But recently FDA has approved Serogroup B meningococcal vaccines (Recombinant) - (Bexsero- and Trumenba-. These two, newly licensed serogroup B meningococcal vaccines are an important step forward for controlling serogroup B meningococcal disease, especially in outbreak settings. For outbreaks caused by serogroup B meningococcal disease, vaccination with a serogroup B meningococcal vaccine is recommended for those 10 years or older identified as being at increased risk because of the outbreak.
Educate students about meningococcal transmission and take preventive measures
Chemoprophylaxis to all against both group B and group C
Vaccine prophylaxis of contacts of Xavier
Vaccine prophylaxis of contacts of Yogendra
Bacteria